Results 131 to 140 of about 38,393 (221)

Risk of acute pancreatitis with DPP‐4 inhibitors versus SGLT2 inhibitors in medication‐naïve individuals with diabetes: A target trial emulation

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3033-3043, April 2026.
Abstract Aims We investigated whether dipeptidyl peptidase‐4 inhibitor (DPP‐4i) use was associated with a higher risk of acute pancreatitis compared with sodium–glucose cotransporter 2 inhibitor (SGLT2i) use in antidiabetic medication‐naïve individuals.
Takashi Tatewaki, Akira Okada, Yuya Kimura, Hideo Yasunaga   +3 more
wiley   +1 more source

The role of pharmacogenetics in the treatment of diabetes mellitus [PDF]

Journal of Medical Biochemistry, 2014
Diabetes mellitus is a heterogeneous group of disorders in which particular disease phenotypes can be characterized by a specific etiology and/or pathogenesis of the disease, but in many cases its classification is greatly impeded due to significant ...
Topić Elizabeta
doaj  

SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3126-3136, April 2026.
Abstract Aims Randomized controlled trials on sodium‐glucose cotransporter 2 (SGLT2) inhibitors have yielded inconsistent findings regarding mortality benefits. It remains unclear whether, and in which subgroups, SGLT2 inhibitors confer survival benefits in older adults with diabetic kidney disease (DKD).
Tatsuhiko Azegami, Hidehiro Kaneko, Akira Okada, Yuta Suzuki, Toshiyuki Ko, Kazuki Aoyama, Takashin Nakayama, Yuya Kimura, Katsuhiko Fujiu, Norifumi Takeda, Hiroyuki Morita, Takashi Yokoo, Koichi Node, Masaomi Nangaku, Norihiko Takeda, Hideo Yasunaga, Kaori Hayashi   +16 more
wiley   +1 more source

Real‐world persistence and dose titration of GLP‐1 receptor agonists in type 2 diabetes: A UK population‐based cohort study by obesity and cardiovascular disease status

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3386-3395, April 2026.
Abstract Aims Real‐world medication use varies across clinical trial and healthcare settings; therefore, we evaluated GLP‐1 receptor agonist (GLP‐1RA) persistence and dose titration among adults with type 2 diabetes in UK primary care, stratified by agent, obesity status, cardiovascular disease (CVD) history, and sex assigned at birth.
Franziska S. Ulrich, Nicola Napoli, Morten Frost Nielsen, Andrea M. Burden   +3 more
wiley   +1 more source

How can we keep impaired glucose tolerance and impaired fasting glucose from progressing to diabetes? [PDF]

, 2010
Lifestyle interventions aimed at weight loss of 5% to 10% of body weight along with moderate aerobic exercise such as brisk walking for 150 minutes a week are the most effective means to prevent impaired fasting glucose (IFG) or impaired glucose ...
Swanson, Ana, Watrin, Kerry, Wilder, Laura   +2 more
core  

Do TZDs increase the risk of heart failure for patients with diabetes? [PDF]

, 2005
Patients with diabetes who take thiazolidinediones (TZDs) have a higher incidence of congestive heart failure (CHF) than those who do not; the incidence of CHF is similar with the use of pioglitazone (Actos), troglitazone (Rezulin), or rosiglitazone ...
Baskin, Serena, Dodson, Sherry, Neher, Jon O.   +2 more
core  

Correspondence to editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis” [PDF]

Clinical and Molecular Hepatology
Hayeon Kim, Min Jeong Park, Myeong Gyu Kim, Kyungim Kim   +3 more
doaj   +1 more source

Comparative effects of second-line oral antidiabetic medications on atrial fibrillation risk in patients with type 2 diabetes: a nationwide retrospective cohort study. [PDF]

Cardiovasc Diabetol
Heo GY, Heo SJ, Ko B, Ko YE, Koh HB, Park CH, Park JT, Han SH, Yoo TH, Kang SW, Han M, Kim HW.   +11 more
europepmc   +1 more source

Comparative risk of the neurodegenerative outcomes between sodium-glucose co-transporter 2 (SGLT2) inhibitors and thiazolidinediones in type 2 diabetes: a multicentre cohort study using the Korean healthcare database (2014-2025). [PDF]

BMJ Open
Park SJ, Kim HJ, Seo M, Byun DW, Suh K, Yoo MH, Yang H, Lee I, Kwon SH, Kim M, Mok JO, Kim DY, Sohn SY, Park RW, Seo WW, Kwon SY, Rhee SY, Kwon JM, Cha JM, Park HK.   +19 more
europepmc   +1 more source

Comparative Longitudinal Evaluation of Systemic Inflammatory Markers in Type 2 Diabetes Treated with Four Oral Antidiabetic Drug Classes. [PDF]

J Clin Med
Yamak M, Çakır S, Uzun S, Cebeci E, Menken Ö, Ozturk S.   +5 more
europepmc   +1 more source